NEW YORK, March 15, 2007 -- On Monday, March 26, The Biotechnology Study Center of NYU School of Medicine will hold its annual awards symposium to honor three outstanding pioneers in biomedical ...

Sana Biotechnology Inc. (NASDAQ:SANA) is one of the best emerging technology stocks to invest in. On December 8, Sana ...

On Monday, April 24, The Biotechnology Study Center of NYU School of Medicine will hold its annual awards symposium to honor three outstanding pioneers in neurobiology and cognition. The Dart/NYU ...

Application of ZFN Technology in Stem Cells has Potential to Yield High Value Research Reagents and Therapeutic Products ST. LOUIS and RICHMOND, Calif., Oct. 29 -- Sigma-Aldrich Corporation and ...

On Tuesday, Sana Biotechnology Inc (NASDAQ:SANA) released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s ...

Biotechnology uses knowledge obtained about organisms at the molecular level to inform diagnostic and therapeutic decisions, create new treatments using stem- and gene-therapies, produce novel ...

In RIT’s biotechnology bachelor’s degree you’ll develop technologies for genetics, agriculture, pharmaceuticals, vaccine development, energy/ environment, forensics, and more. Hands on Experience: ...

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% ...

UNITY Biotechnology, Inc. has announced that it will present data from its ASPIRE Phase 2B study on its senolytic candidate, UBX1325, targeting diabetic macular edema at the upcoming ARVO 2025 Annual ...

CHICAGO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today published a ...

Unity Biotechnology, Inc. (NASDAQ:UBX) stock plummeted on Monday after the company released results from its latest study. The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients ...

Shares of both Ultragenyx and Mereo BioPharma were seeing record selloffs after disappointing trial results for setrusumab.